We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Diatron MI Plc

Develops, manufactures and markets hematology analyzers, clinical chemistry analyzers, and associated reagents for hu... read more Featured Products: More products

Download Mobile App





Diatron Exhibits Advanced Hematology and Clinical Chemistry Analyzers at MEDICA 2022

By LabMedica International staff writers
Posted on 16 Nov 2022
Print article
Image: Diatron has been present at MEDICA for the past 15 years at the same booth location (Photo courtesy of Diatron)
Image: Diatron has been present at MEDICA for the past 15 years at the same booth location (Photo courtesy of Diatron)

Diatron (Budapest, Hungary) is exhibiting its advanced hematology analyzers and clinical chemistry analyzers, along with associated reagents at the 2022 edition of MEDICA, the world's largest trade fair for medical technology, being held from 14 to 17 November in Düsseldorf, Germany.

At MEDICA 2022, Diatron is exhibiting the KleeYa open, flexible CLIA platform which provides a unique approach to the use of different bead-based CLIA technologies, offering superior assay performance and providing ease of use with cost containment. Diatron’s KleeYa, a highly flexible, fast and sensitive random access CLIA platform for immunoassay menu, handles tests from various providers and is able to combine a wide variety of assay designs.

Also on display at the Diatron booth at MEDICA is the company’s new P780 clinical chemistry analyzer alongside the Aquila 3-part differential hematology analyzer. The Diatron Aquila is an innovative and revolutionary hematology analyzer that can be used in any testing location and application where high quality CBC results are desired. The Diatron Aquila can be used to perform complete CBC with human blood, collected in either standard EDTA collection tubes (Vacutainer type) or with micro sampling tubes. It delivers accurate results with regular and micro-sampling collection tubes with only 20 μl blood required and results in less than one minute. The QC menu offers the user the opportunity to use secondary QC limits for all parameters providing the extended QC option. The Diatron Aquila featuring the company’s latest technology offers an optimal testing solution for both experienced and inexperienced users and practices that require a high quality hematology analyzer.

Related Links:
Diatron 

Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0
New
Gold Member
LEISHMANIA Test
LEISHMANIA ELISA
New
Hepatitis B Test
OnSite HBsAg Rapid Test
New
Automated Immunoassay Analyzer
Phadia 1000

Print article

Channels

Molecular Diagnostics

view channel
Image: A coronal MRI section shows a high-intensity focused ultrasound lesion in the left thalamus of the brain (Photo courtesy of UT Southwestern Medical Center)

Newly Identified Stroke Biomarkers Pave Way for Blood Tests to Quickly Diagnose Brain Injuries

Each year, nearly 800,000 individuals in the U.S. experience a stroke, which occurs when blood flow to specific areas of the brain is insufficient, causing brain cells to die due to a lack of oxygen.... Read more

Immunology

view channel
Image: The discovery of biomarkers could improve endometrial cancer treatment (Photo courtesy of Mount Sinai)

Simple Blood Test Could Help Choose Better Treatments for Patients with Recurrent Endometrial Cancer

Endometrial cancer, which develops in the lining of the uterus, is the most prevalent gynecologic cancer in the United States, affecting over 66,000 women annually. Projections indicate that in 2025, around... Read more

Pathology

view channel
Image: As tumor cells flow through these microfluidic chambers, they are subjected to increasing shear stress and sorted based on their adhesion strength (Photo courtesy of UC San Diego)

Microfluidic Device Assesses Stickiness of Tumor Cells to Predict Cancer Spread

Ductal carcinoma in situ (DCIS), a type of early-stage breast cancer, is often referred to as stage zero breast cancer. In many cases, it remains harmless and does not spread beyond the milk ducts where... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.